Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOURMALINE: durvalumab plus gemcitabine-based chemotherapy for first-line advanced biliary tract cancer
2022-502043-35-01Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of durvalumab in biliary cancer, cholangiocarcinoma (CCA), gallbladder cancer and 1 more, sponsored by AstraZeneca. Primary endpoint: Incidence of Grade 3 or 4 protocol-related adverse events within 6 months. Planned start Apr 2024; status: authorised.
02
Drugs
durvalumab
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on 2022-502043-35-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502043-35-01.